治疗胆囊切除术和疝修补术后疼痛的经皮耳廓神经调控(神经刺激):随机、双掩蔽、假对照试验研究

Brian M Ilfeld, Wendy B Abramson, Brenton Alexander, Jacklynn F Sztain, Engy T Said, Ryan C Broderick, Bryan J Sandler, Jay J Doucet, Laura M Adams, Baharin Abdullah, Brannon J Cha, John J Finneran
{"title":"治疗胆囊切除术和疝修补术后疼痛的经皮耳廓神经调控(神经刺激):随机、双掩蔽、假对照试验研究","authors":"Brian M Ilfeld, Wendy B Abramson, Brenton Alexander, Jacklynn F Sztain, Engy T Said, Ryan C Broderick, Bryan J Sandler, Jay J Doucet, Laura M Adams, Baharin Abdullah, Brannon J Cha, John J Finneran","doi":"10.1136/rapm-2024-105283","DOIUrl":null,"url":null,"abstract":"Background Percutaneous auricular nerve stimulation (neuromodulation) involves implanting electrodes around the ear and administering an electric current. A device is currently available within the USA cleared to treat symptoms from opioid withdrawal, and multiple reports suggest a possible postoperative analgesic effect. The current randomized controlled pilot study was undertaken to (1) determine the feasibility and optimize the protocol for a subsequent definitive clinical trial; and (2) estimate the treatment effect of auricular neuromodulation on postoperative pain and opioid consumption following two ambulatory surgical procedures. Methods Within the recovery room following cholecystectomy or hernia repair, an auricular neuromodulation device (NSS-2 Bridge, Masimo, Irvine, California, USA) was applied. Participants were randomized to 5 days of either electrical stimulation or sham in a double-blinded fashion. Results In the first 5 days, the median (IQR) pain level for active stimulation (n=15) was 0.6 (0.3–2.4) vs 2.6 (1.1–3.7) for the sham group (n=15) (p=0.041). Concurrently, the median oxycodone use for the active stimulation group was 0 mg (0–1), compared with 0 mg (0–3) for the sham group (p=0.524). Regarding the highest pain level experienced over the entire 8-day study period, only one participant (7%) who received active stimulation experienced severe pain, versus seven (47%) in those given sham (p=0.031). Conclusions Percutaneous auricular neuromodulation reduced pain scores but not opioid requirements during the initial week after cholecystectomy and hernia repair. Given the ease of application as well as a lack of systemic side effects and reported complications, a definitive clinical trial appears warranted. Trial registration number [NCT05521516][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT05521516&atom=%2Frapm%2Fearly%2F2024%2F02%2F21%2Frapm-2024-105283.atom","PeriodicalId":21046,"journal":{"name":"Regional Anesthesia & Pain Medicine","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Percutaneous auricular neuromodulation (nerve stimulation) for the treatment of pain following cholecystectomy and hernia repair: a randomized, double-masked, sham-controlled pilot study\",\"authors\":\"Brian M Ilfeld, Wendy B Abramson, Brenton Alexander, Jacklynn F Sztain, Engy T Said, Ryan C Broderick, Bryan J Sandler, Jay J Doucet, Laura M Adams, Baharin Abdullah, Brannon J Cha, John J Finneran\",\"doi\":\"10.1136/rapm-2024-105283\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Percutaneous auricular nerve stimulation (neuromodulation) involves implanting electrodes around the ear and administering an electric current. A device is currently available within the USA cleared to treat symptoms from opioid withdrawal, and multiple reports suggest a possible postoperative analgesic effect. The current randomized controlled pilot study was undertaken to (1) determine the feasibility and optimize the protocol for a subsequent definitive clinical trial; and (2) estimate the treatment effect of auricular neuromodulation on postoperative pain and opioid consumption following two ambulatory surgical procedures. Methods Within the recovery room following cholecystectomy or hernia repair, an auricular neuromodulation device (NSS-2 Bridge, Masimo, Irvine, California, USA) was applied. Participants were randomized to 5 days of either electrical stimulation or sham in a double-blinded fashion. Results In the first 5 days, the median (IQR) pain level for active stimulation (n=15) was 0.6 (0.3–2.4) vs 2.6 (1.1–3.7) for the sham group (n=15) (p=0.041). Concurrently, the median oxycodone use for the active stimulation group was 0 mg (0–1), compared with 0 mg (0–3) for the sham group (p=0.524). Regarding the highest pain level experienced over the entire 8-day study period, only one participant (7%) who received active stimulation experienced severe pain, versus seven (47%) in those given sham (p=0.031). Conclusions Percutaneous auricular neuromodulation reduced pain scores but not opioid requirements during the initial week after cholecystectomy and hernia repair. Given the ease of application as well as a lack of systemic side effects and reported complications, a definitive clinical trial appears warranted. Trial registration number [NCT05521516][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT05521516&atom=%2Frapm%2Fearly%2F2024%2F02%2F21%2Frapm-2024-105283.atom\",\"PeriodicalId\":21046,\"journal\":{\"name\":\"Regional Anesthesia & Pain Medicine\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regional Anesthesia & Pain Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/rapm-2024-105283\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regional Anesthesia & Pain Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/rapm-2024-105283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景经皮耳神经刺激(神经调控)是指在耳朵周围植入电极并施加电流。目前,美国有一种设备被批准用于治疗阿片类药物戒断症状,多份报告显示该设备可能具有术后镇痛效果。目前进行的随机对照试验研究旨在:(1)确定可行性并优化方案,以便随后进行明确的临床试验;(2)估计耳神经调控对两种非卧床手术后的术后疼痛和阿片类药物消耗的治疗效果。方法 在胆囊切除术或疝气修补术后的恢复室中使用耳神经调控装置(NSS-2 Bridge,Masimo,美国加利福尼亚州欧文市)。以双盲方式随机对参与者进行为期 5 天的电刺激或假刺激。结果 在前 5 天,主动刺激组(15 人)的疼痛水平中位数(IQR)为 0.6(0.3-2.4),假刺激组(15 人)为 2.6(1.1-3.7)(P=0.041)。同时,主动刺激组使用的羟考酮中位数为 0 毫克(0-1),而假体组为 0 毫克(0-3)(P=0.524)。关于在整个 8 天研究期间经历的最高疼痛程度,接受主动刺激的受试者中只有一人(7%)经历过剧烈疼痛,而接受假刺激的受试者中有七人(47%)经历过剧烈疼痛(P=0.031)。结论 在胆囊切除术和疝气修补术后的最初一周,经皮耳廓神经调控降低了疼痛评分,但没有降低阿片类药物的需求量。鉴于其应用简便,且无全身副作用和并发症,似乎有必要进行一项明确的临床试验。试验注册号 [NCT05521516][1].[1]:/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT05521516&atom=%2Frapm%2Fearly%2F2024%2F02%2F21%2Frapm-2024-105283.atom
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Percutaneous auricular neuromodulation (nerve stimulation) for the treatment of pain following cholecystectomy and hernia repair: a randomized, double-masked, sham-controlled pilot study
Background Percutaneous auricular nerve stimulation (neuromodulation) involves implanting electrodes around the ear and administering an electric current. A device is currently available within the USA cleared to treat symptoms from opioid withdrawal, and multiple reports suggest a possible postoperative analgesic effect. The current randomized controlled pilot study was undertaken to (1) determine the feasibility and optimize the protocol for a subsequent definitive clinical trial; and (2) estimate the treatment effect of auricular neuromodulation on postoperative pain and opioid consumption following two ambulatory surgical procedures. Methods Within the recovery room following cholecystectomy or hernia repair, an auricular neuromodulation device (NSS-2 Bridge, Masimo, Irvine, California, USA) was applied. Participants were randomized to 5 days of either electrical stimulation or sham in a double-blinded fashion. Results In the first 5 days, the median (IQR) pain level for active stimulation (n=15) was 0.6 (0.3–2.4) vs 2.6 (1.1–3.7) for the sham group (n=15) (p=0.041). Concurrently, the median oxycodone use for the active stimulation group was 0 mg (0–1), compared with 0 mg (0–3) for the sham group (p=0.524). Regarding the highest pain level experienced over the entire 8-day study period, only one participant (7%) who received active stimulation experienced severe pain, versus seven (47%) in those given sham (p=0.031). Conclusions Percutaneous auricular neuromodulation reduced pain scores but not opioid requirements during the initial week after cholecystectomy and hernia repair. Given the ease of application as well as a lack of systemic side effects and reported complications, a definitive clinical trial appears warranted. Trial registration number [NCT05521516][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT05521516&atom=%2Frapm%2Fearly%2F2024%2F02%2F21%2Frapm-2024-105283.atom
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信